184 related articles for article (PubMed ID: 21682819)
1. Reduced early prophylaxis of children with haemophilia in a developing country, Turkey.
Celkan T; Ozdemir N
Haemophilia; 2011 Sep; 17(5):e840-1. PubMed ID: 21682819
[No Abstract] [Full Text] [Related]
2. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development.
Kurnik K; Bidlingmaier C; Engl W; Chehadeh H; Reipert B; Auerswald G
Haemophilia; 2010 Mar; 16(2):256-62. PubMed ID: 19878331
[TBL] [Abstract][Full Text] [Related]
3. Complete immunotolerance induction after FEIBA prophylaxis in a haemophilia A patient with high-titre inhibitor.
Nanishi E; Ohga S; Doi T; Ishimura M; Ihara K; Takada H; Shima M; Hara T
Haemophilia; 2012 May; 18(3):e75-7. PubMed ID: 22404696
[No Abstract] [Full Text] [Related]
4. Early prophylaxis/FVIII tolerization regimen that avoids immunological danger signals is still effective in minimizing FVIII inhibitor developments in previously untreated patients--long-term follow-up and continuing experience.
Auerswald G; Bidlingmaier C; Kurnik K
Haemophilia; 2012 Jan; 18(1):e18-20. PubMed ID: 21951822
[No Abstract] [Full Text] [Related]
5. Difficult clinical challenges in haemophilia: international experiential perspectives.
Forsyth AL; Giangrande P; Hay CR; Kenet G; Kessler CM; Knöbl PN; Llinás A; Santagostino E; Young G
Haemophilia; 2012 Jul; 18 Suppl 5():39-45. PubMed ID: 22757683
[TBL] [Abstract][Full Text] [Related]
6. Inhibitor development, immune tolerance and prophylaxis in haemophilia A--the need for an evidence-based approach.
Mannucci PM; Abshire T; Dimichele D; Santagostino E; Blanchette V
Haemophilia; 2006 Jul; 12(4):429-34. PubMed ID: 16834746
[No Abstract] [Full Text] [Related]
7. Secondary prophylaxis in an adult patient with severe haemophilia A. Factor VIII consumption and effectiveness.
Schlenkrich S; Schubert C
Hamostaseologie; 2013 Aug; 33(3):241-4. PubMed ID: 23435748
[TBL] [Abstract][Full Text] [Related]
8. How I treat inhibitors in haemophilia.
Makris M; Hay CR; Gringeri A; D'Oiron R
Haemophilia; 2012 Jul; 18 Suppl 4():48-53. PubMed ID: 22726083
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting.
Musso R; Santagostino E; Faradji A; Iorio A; van der Meer J; Ingerslev J; Lambert T; Maas-Enriquez M; Gorina E;
Thromb Haemost; 2008 Jan; 99(1):52-8. PubMed ID: 18217134
[TBL] [Abstract][Full Text] [Related]
10. Radiosynoviorthesis in children with haemophilia.
Pasta G; Mancuso ME; Perfetto OS; Solimeno LP
Hamostaseologie; 2009 Oct; 29 Suppl 1():S62-4. PubMed ID: 19763357
[TBL] [Abstract][Full Text] [Related]
11. Considerations in individualizing prophylaxis in patients with haemophilia A.
Valentino LA
Haemophilia; 2014 Sep; 20(5):607-15. PubMed ID: 24712891
[TBL] [Abstract][Full Text] [Related]
12. Short and long-term management of haemophilia A patient requiring heart valve surgery.
Zatorska K; Orłowska-Baranowska E; Abramczuk E; Kuśmierczyk M; Greszata L; Grabowski M; Stępińska J; Baran B; Windyga J
Haemophilia; 2012 Jul; 18(4):e352-4. PubMed ID: 22530726
[No Abstract] [Full Text] [Related]
13. How we manage prostate biopsy and prostate cancer therapy in men with haemophilia.
Fogarty PF; Kouides P
Haemophilia; 2012 May; 18(3):e88-90. PubMed ID: 22500858
[TBL] [Abstract][Full Text] [Related]
14. [Laboratory monitoring of efficiency of different approaches to the therapy of patients with inhibitor form of haemophilia A].
Nabieva MI
Lik Sprava; 2009; (1-2):59-61. PubMed ID: 19953993
[TBL] [Abstract][Full Text] [Related]
15. A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center.
Dodd C; Watts RG
Haemophilia; 2012 Jul; 18(4):561-7. PubMed ID: 22221939
[TBL] [Abstract][Full Text] [Related]
16. Short-term low-dose secondary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: a multi-centre pilot study in China.
Tang L; Wu R; Sun J; Zhang X; Feng X; Zhang X; Luke KH; Poon MC
Haemophilia; 2013 Jan; 19(1):27-34. PubMed ID: 23231016
[TBL] [Abstract][Full Text] [Related]
17. Development of factor VIII inhibitors in two patients with moderate haemophilia A.
Paschal RD; Meeks SL; Neff AT
Haemophilia; 2013 Jan; 19(1):e55-7. PubMed ID: 23171275
[No Abstract] [Full Text] [Related]
18. Personalized prophylaxis.
Collins PW
Haemophilia; 2012 Jul; 18 Suppl 4():131-5. PubMed ID: 22726096
[TBL] [Abstract][Full Text] [Related]
19. Immune response against serial infusion of factor VIII antigen through an implantable venous-access device system in haemophilia A mice.
Madoiwa S; Kobayashi E; Kashiwakura Y; Sakata A; Yasumoto A; Ohmori T; Mimuro J; Sakata Y
Haemophilia; 2012 May; 18(3):e323-30. PubMed ID: 22044430
[TBL] [Abstract][Full Text] [Related]
20. Comparing prophylaxis with episodic treatment in haemophilia A: implications for clinical practice.
Manco-Johnson M
Haemophilia; 2007 Sep; 13 Suppl 2():4-9. PubMed ID: 17685917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
